Brand and Other Names:Qutenza
- Classes: Analgesics, Topical
Dosing & Uses
Dosage Forms & Strengths
- 8%; contains 640mcg/sq.cm (179mg/patch)
Qutenza is indicated for neuropathic pain associated wtih postherpetic neuralgia
Single 60-minute application of up to 4 patches to dry, intact (unbroken) skin
May repeat no more frequently than q3Months
Application preparation (Quetenza)
- Use nitrile gloves during application process, latex gloves do not provide adequate protection
- Clipping hair (do not shave) if necessary
- Gently wash treatment area with mild soap and water, dry thoroughly
- Patch may be cut to match size and shape of treatment area (cut to size/shape before removing protective release liner)
- Pretreat area with topical anesthetic to reduce pain associated with patch application
- Apply patch within 2 hours of opening package
Patch removal (Qutenza)
- Gently remove and slowly roll them inward (avoid aerosolization)
- Cleanse skin by generously applying cleansing gel (supplied with patch) to affected area, leave on for at least 1 minute, then remove with dry wipe and gently wash area with mild soap and water
Safety and efficacy not established
Transient increased pain at application site (63%)
Application site erythema (42%)
Pruritus at application site (2%)
Papules at application site (6%)
Skin dryness at application site (2%)
Monitor for at least 1 hour after patch application because of risk for increased blood pressure
Do not apply to face or scalp to avoid exposure to eyes or mucous membranes
Remove patch gently to avoid aerosolization (airborne capsaicin can result in coughing or sneezing)
Treated area may be sensitive to heat for several days (eg, hot water, direct sunlight, vigorous exercise)
Use caution in patients with uncontrolled hypertension, history of cerebrovascular events
Pregnancy & Lactation
Pregnancy Category: B
Lactation: Not known whether distributed in breast milk, do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Transient receptor potential vanilloid-1 (TRPV1) agonist; topical application causes initial TRPV1 stimulation that may cause pain, followed by pain relief by reduction in TRPV1-expressing nociceptive nerve endings
Absorption: systemic absorption negligible
Peak plasma concentration: Transient, low (<5 ng/mL) systemic exposure in one-third of patients following 60-min application; 4.6 ng/mL was highest level detected
Half-life: 1.64 hr
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs